Published in Anticancer Res on December 17, 1993
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res (1987) 2.85
Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer (1984) 2.55
Radiosensitizers of hypoxic cells in solid tumors. Cancer Treat Rev (1976) 2.33
Cell kinetics and radiation biology. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 1.91
Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys (1986) 1.84
Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer. Radiat Res (1978) 1.80
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res (1999) 1.79
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res (2001) 1.75
The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys (1989) 1.71
Hypoxic cell radiosensitizers: comparative tests of some electron affinic compounds using epidermal cell survival in vivo. Radiat Res (1974) 1.66
Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer (1982) 1.65
Endothelial-cell proliferation in experimental tumours. Br J Cancer (1982) 1.63
EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys (1995) 1.59
EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol (1995) 1.58
Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer (1985) 1.57
Tests of two electron-affinic radiosensitizers in vivo using regrowth of an experimental carcinoma. Radiat Res (1975) 1.57
Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys (2000) 1.55
Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet (1979) 1.55
The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys (1987) 1.48
Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer (1985) 1.47
Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer (1988) 1.44
The cellular proliferation kinetics of animal tumors. Cancer Res (1970) 1.42
Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol (1983) 1.42
Entering the third millennium after a century of ionizing radiation in science and oncology. Acta Oncol (1999) 1.38
The relationship between the 'cell loss factor' and the immediate response to radiation in animal tumours. Eur J Cancer (1972) 1.37
In vitro and in vivo labelling of animal tumours with tritiated thymidine. Cell Tissue Kinet (1973) 1.36
Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest (1990) 1.36
The use of rodent tumors in experimental cancer therapy. Conclusions and recommendations from an international workshop. Cancer Res (1985) 1.33
Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res (2001) 1.32
Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer (1999) 1.30
Proliferation studies of the endothelial and smooth muscle cells of the mouse mesentery after irradiation. Cell Tissue Kinet (1980) 1.27
Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas. Cell Tissue Kinet (1982) 1.27
Changes in the rate of repopulation during multifraction irradiation of mouse skin. Br J Radiol (1973) 1.21
Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res (1989) 1.20
Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol (1984) 1.20
Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer (1989) 1.19
Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res (1998) 1.19
A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys (1985) 1.18
Late radiation damage in the mouse bladder as measured by increased urination frequency. Radiat Res (1978) 1.18
The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res (1995) 1.18
The response of a transplantable tumor to fractionated irradiation. 1. X rays and the hypoxic cell radiosensitizer Ro-07-0582. Radiat Res (1976) 1.17
Tumour blood flow changes induced by application of electric pulses. Eur J Cancer (1999) 1.17
Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer (1993) 1.17
Optimum fractionation of the C3H mouse mammary carcinoma using x-rays, the hypoxic-cell radiosensitizer Ro-07-0582, or fast neutrons. Int J Radiat Oncol Biol Phys (1977) 1.16
Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol (1989) 1.13
Hypoxic cell sensitization by misonidazole in vivo and in vitro. Br J Radiol (1978) 1.12
Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys (2000) 1.12
Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res (2000) 1.11
Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int J Radiat Biol (1991) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
The cell proliferation kinetics of four experimental tumors after acute X-irradiation. Cancer Res (1971) 1.09
Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol (1998) 1.09
Targeting gene therapy to cancer: a review. Oncol Res (1997) 1.08
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer (2010) 1.07
Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol (1996) 1.06
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer (1998) 1.05
Intermittent blood flow in the KHT sarcoma--flow cytometry studies using Hoechst 33342. Br J Cancer (1990) 1.04
Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer (2001) 1.03
Tumour regression as a guide to prognosis: a study with experimental animals. Br J Radiol (1977) 1.03
Skin reactions in mice after multifraction x-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med (1974) 1.03
The response of six mouse tumours to combined heat and X rays: implications for therapy. Br J Radiol (1979) 1.02
Dose-response relationships for human tumors: implications for clinical trials of dose modifying agents. Int J Radiat Oncol Biol Phys (1984) 1.01
The effects of melphalan and misonidazole on the vasculature of a murine sarcoma. Br J Cancer (1987) 1.01
Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res (1987) 1.01
The response of a mouse sarcoma to single and divided doses of x-rays and fast neutrons. Br J Cancer (1974) 1.00
In vivo assessment of basic 2-nitroimidazole radiosensitizers. Br J Cancer (1982) 1.00
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer (2000) 0.99
Proliferation kinetics of the mouse bladder after irradiation. Cell Tissue Kinet (1980) 0.99
Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res (2001) 0.99
Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys (1989) 0.98
Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol (1999) 0.98
Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer (1995) 0.98
Cytotoxicity and radiosensitization in mouse and man. Br J Radiol (1978) 0.98
A review of hypoxic cell radiosensitization in experimental tumors. Pharmacol Ther (1979) 0.97
Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer (1990) 0.97
Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.97
The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res (2001) 0.97
Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed (1999) 0.97
Distribution of Photofrin between tumour cells and tumour associated macrophages. Br J Cancer (1991) 0.96
Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res (1990) 0.96
The magnitude of hypoxic cell cytotoxicity of misonidazole in human tumours. Br J Radiol (1978) 0.96
Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. Br J Cancer (1982) 0.96
The effect of vascular occlusion on the thermal sensitization of a mouse tumour. Br J Radiol (1978) 0.95
Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol (1999) 0.95
Is tumour radiosensitization by misonidazole a general phenomenon? Br J Cancer (1980) 0.95
Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer (2000) 0.95
Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res (1997) 0.94
Ischaemia induced cell death in tumors: importance of temperature and pH. Int J Radiat Oncol Biol Phys (1994) 0.94
Radiosensitization of solid tumors by nitroimidazoles. Int J Radiat Oncol Biol Phys (1978) 0.94
The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. Br J Cancer (1995) 0.94
Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration. Radiother Oncol (1996) 0.93
The effect of hypoxia and low pH on the cytotoxicity of chlorambucil. Int J Radiat Oncol Biol Phys (1992) 0.93
The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother Oncol (1994) 0.93
Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide. Cancer Res (1995) 0.93
Optimum fractionation in X-ray treatment of C3H mouse mammary tumours. Br J Radiol (1974) 0.93
Cell sorting with Hoechst or carbocyanine dyes as perfusion probes in spheroids and tumors. Methods Cell Biol (1990) 0.92